Cargando…
The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis
The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primar...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705897/ https://www.ncbi.nlm.nih.gov/pubmed/29270438 http://dx.doi.org/10.1155/2017/9257930 |
_version_ | 1783282118690865152 |
---|---|
author | Nasrallah, Mona P. Abi Khalil, Charbel Refaat, Marwan M. |
author_facet | Nasrallah, Mona P. Abi Khalil, Charbel Refaat, Marwan M. |
author_sort | Nasrallah, Mona P. |
collection | PubMed |
description | The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primarily conducted to establish that goal. Some had neutral effects, while there were positively beneficial outcomes with more recent studies. Hospitalization for congestive heart failure has also been a heterogeneous finding among the different classes of GLT, with drug outcomes ranging from risky to beneficial. The current review selectively focuses on the evidence for CV outcomes for each class of GLT and summarizes the existing guidelines with regard to these drugs in heart disease. Moreover, it illustrates the dynamic status in the development of evidence. Finally, the review enables healthcare providers to formulate a plan for hypoglycemic therapy which will optimize CV health, in a patient-centered manner. |
format | Online Article Text |
id | pubmed-5705897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-57058972017-12-21 The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis Nasrallah, Mona P. Abi Khalil, Charbel Refaat, Marwan M. Biomed Res Int Review Article The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primarily conducted to establish that goal. Some had neutral effects, while there were positively beneficial outcomes with more recent studies. Hospitalization for congestive heart failure has also been a heterogeneous finding among the different classes of GLT, with drug outcomes ranging from risky to beneficial. The current review selectively focuses on the evidence for CV outcomes for each class of GLT and summarizes the existing guidelines with regard to these drugs in heart disease. Moreover, it illustrates the dynamic status in the development of evidence. Finally, the review enables healthcare providers to formulate a plan for hypoglycemic therapy which will optimize CV health, in a patient-centered manner. Hindawi 2017 2017-11-14 /pmc/articles/PMC5705897/ /pubmed/29270438 http://dx.doi.org/10.1155/2017/9257930 Text en Copyright © 2017 Mona P. Nasrallah et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Nasrallah, Mona P. Abi Khalil, Charbel Refaat, Marwan M. The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis |
title | The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis |
title_full | The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis |
title_fullStr | The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis |
title_full_unstemmed | The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis |
title_short | The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis |
title_sort | landscape of glucose-lowering therapy and cardiovascular outcomes: from barren land to metropolis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705897/ https://www.ncbi.nlm.nih.gov/pubmed/29270438 http://dx.doi.org/10.1155/2017/9257930 |
work_keys_str_mv | AT nasrallahmonap thelandscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis AT abikhalilcharbel thelandscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis AT refaatmarwanm thelandscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis AT nasrallahmonap landscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis AT abikhalilcharbel landscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis AT refaatmarwanm landscapeofglucoseloweringtherapyandcardiovascularoutcomesfrombarrenlandtometropolis |